Source: MrrTrack model
Estimated active users × assumed paying share × estimated monthly revenue per customer. We distinguish B2B, B2C and creator tools, and use comparable revenue when available. These are model assumptions, not measured sales.
Indicative range $65–$5.2k
Share of monthly visits
Map unavailable. Country shares are listed alongside.
Select a country to locate it
A cardiovascular-focused delivery model that protects the evidence chain between visits—wear-time continuity, ECG quality, symptom capture, and retention—backed by real-time oversight and human follow-through.
Share of monthly visits
Updated: 09/01/2026
Traffic, revenue and acquisition: the data behind the product.
Catalog updated on
A cardiovascular-focused delivery model that protects the evidence chain between visits—wear-time continuity, ECG quality, symptom capture, and retention—backed by real-time oversight and human follow-through.
Official website delvehealth.comClinical StudyPal receives an estimated 3,030 visits in September 2026.
This represents a change of +1,289.9% compared with August 2026 (218 visits).
These are estimated visits, not unique users or paying customers. Traffic growth does not establish sales growth.
| Month | Visits |
|---|---|
| 970 | |
| 218 | |
| 3,030 |
Clinical StudyPal has an estimated monthly revenue of $580. This is an estimate, not company-reported revenue or payment-verified MRR.The model uses available product, traffic and comparable SaaS signals; its assumptions remain uncertain.
The leading countries for visits to Clinical StudyPal are: United States (69.7%), India (30.3%). These shares describe website traffic, not the location of paying customers.
The recorded channels include: Search (37.2%), Direct (27.9%), Social (7.8%).Coverage may be partial: a missing value does not establish that a channel is unused. These visits do not measure conversions or advertising returns.
The YouTube and Meta Ads sections let you explore collected mentions and creatives. Access depends on your account and subscription.
Explore acquisition dataA sufficiently relevant selection of similar SaaS is not available for this profile.Similarity is assessed from available descriptions, categories and use cases. It does not guarantee equivalent features or pricing.
Answers based on the data available in this profile.
Clinical StudyPal receives an estimated 3,030 visits in September 2026. These are estimated visits, not unique users or paying customers. Traffic growth does not establish sales growth.
Clinical StudyPal has an estimated monthly revenue of $580. This is an estimate, not company-reported revenue or payment-verified MRR.The model uses available product, traffic and comparable SaaS signals; its assumptions remain uncertain.
This represents a change of +1,289.9% compared with August 2026 (218 visits). These are estimated visits, not unique users or paying customers. Traffic growth does not establish sales growth.
The leading countries for visits to Clinical StudyPal are: United States (69.7%), India (30.3%). These shares describe website traffic, not the location of paying customers.
A sufficiently relevant selection of similar SaaS is not available for this profile.Similarity is assessed from available descriptions, categories and use cases. It does not guarantee equivalent features or pricing.
The catalog data was last updated on October 20, 2026.The latest available traffic month is September 2026.Traffic periods, collection dates and revenue source dates can differ.
Matched by what the product does. Traffic only breaks ties.
Share calculated from Meta's reported reach breakdown. Spend by country is not published.